2cureX AB (OSTO:2CUREX) FCF Margin % : -8,883.91% (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is 2cureX AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. 2cureX AB's Free Cash Flow for the three months ended in Sep. 2023 was kr-7.73 Mil. 2cureX AB's Revenue for the three months ended in Sep. 2023 was kr0.09 Mil. Therefore, 2cureX AB's FCF Margin % for the quarter that ended in Sep. 2023 was -8,883.91%.

As of today, 2cureX AB's current FCF Yield % is -481.39%.

The historical rank and industry rank for 2cureX AB's FCF Margin % or its related term are showing as below:

OSTO:2CUREX' s FCF Margin % Range Over the Past 10 Years
Min: -31694.44 Med: -20480.2 Max: -9265.96
Current: -11978.71

During the past 8 years, the highest FCF Margin % of 2cureX AB was -9265.96%. The lowest was -31694.44%. And the median was -20480.20%.

OSTO:2CUREX's FCF Margin % is ranked worse than
92.36% of 1047 companies
in the Biotechnology industry
Industry Median: -143.92 vs OSTO:2CUREX: -11978.71

2cureX AB FCF Margin % Historical Data

The historical data trend for 2cureX AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2cureX AB FCF Margin % Chart

2cureX AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-31,694.44

2cureX AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
FCF Margin %	Get a 7-Day Free Trial															-96,750.00	-3,546.34	-79,192.31	-13,276.12	-8,883.91

Competitive Comparison of 2cureX AB's FCF Margin %

For the Biotechnology subindustry, 2cureX AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

2cureX AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2cureX AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where 2cureX AB's FCF Margin % falls into.

2cureX AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

2cureX AB's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-28.525	/	0.09
	=	-31,694.44 %

2cureX AB's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-7.729	/	0.087
	=	-8,883.91 %

2cureX AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of 2cureX AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

2cureX AB (OSTO:2CUREX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2cureX AB (OSTO:2CUREX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

2QE:Germany

Address

Fruebjergvej 3, Copenhagen, DNK, DK-2100

Website

https://www.2curex.com

2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.

2cureX AB (OSTO:2CUREX) Headlines

No Headlines